<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806520</url>
  </required_header>
  <id_info>
    <org_study_id>03671-08-C</org_study_id>
    <nct_id>NCT00806520</nct_id>
  </id_info>
  <brief_title>Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control</brief_title>
  <official_title>Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR,
      sitagliptin, or pioglitazone. The CGM measurements collected will help determine the
      characteristics of glucose control prior to treatment and during treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in the Amylin BCB106 Protocol Main Study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  type 2 diabetes

          -  A1c 7.1 - 11

          -  BMI 25 - 45

          -  stable weight for 3 months before screening

          -  fasting glucose &lt; 280 at screening

          -  stable dose of metformin for at least 2 months before screening

          -  not being treated with or on a stable dose of hormone replacement therapy, oral
             contraceptives, anti-hypertensive agents, lipid lowering agents, thyroid replacement
             therapy, anti-depressants, drugs known to affect body weight

          -  male or female, non-lactating, non-pregnant and willing to use birth control

          -  lab values that are not clinically significant at screening

          -  physical exam and ECG that are not clinically significant at screening

          -  able to read, understand, and sign consent form

        Exclusion Criteria:

          -  liver disease

          -  renal disease

          -  cardiovascular disease

          -  gastroparesis

          -  cancer within 5 years of screening

          -  macular edema

          -  chronic infections

          -  drug or alcohol abuse

          -  fasting triglycerides &gt; or = 600 at screening

          -  previous exposure to exenatide LAR

          -  has donated blood within 60 days of screening or is planning to donate during the
             study

          -  has had a major surgery or blood transfusion within 2 months before screening

          -  is currently being treated or is expecting to be treated with Byetta, Januvia, SU,
             TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin,
             insulin, systemic corticosteroids, lopid or rifampin

          -  has received an investigational drug within 1 month before screening

          -  has allergies or hypersensitivity to any component of the study drug

          -  has previously had an adverse event related to TZD or Januvia

          -  is an immediate family member of the study sight or directly affiliated

          -  is employed by Amylin, Lilly or Alkermes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M. Bergenstal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger S. Mazze, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert M. Cuddihy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elinor (Ellie) S. Strock, APRN, BS,CDE</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Medical Group</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Diabetes Care Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Continuous Glucose Monitoring</keyword>
  <keyword>Exenatide Once Weekly or</keyword>
  <keyword>Januvia or</keyword>
  <keyword>Actos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

